Dr. Rosenfelt studies cancers of the immune system, particularly B-cell lymphomas, which include conditions like follicular and diffuse histiocytic lymphomas. He evaluates the effectiveness of various treatments, including combinations of chemotherapy, targeted drugs, and immunotherapies to enhance patient survival rates. His research is particularly focused on challenging cases where standard treatments have failed, and he aims to develop better strategies for managing these aggressive cancers, improving the quality of life for patients undergoing treatment.
Key findings
In a study on double hit and triple hit B-cell lymphomas, a combination of drugs reduced cancer cell growth significantly, leading to better patient outcomes.
In a phase 2 trial of 92 patients with follicular B-cell lymphoma, 60% had a positive response to a new immunotherapy treatment, with an average event-free survival of 15 months.
Using a specific chemotherapy regimen combined with rituximab for relapsed B-cell lymphoma, 10 out of 15 patients achieved cancer-free stem cells prior to transplant, greatly enhancing their chances of recovery.
From his research on diffuse histiocytic lymphoma (DHL), 54% of patients achieved complete remission after treatment, with those in remission showing survival rates over 36 months.
Frequently asked questions
Does Dr. Rosenfelt study B-cell lymphoma?
Yes, Dr. Rosenfelt specializes in various forms of B-cell lymphoma, including aggressive types like double hit and triple hit.
What treatments has Dr. Rosenfelt researched?
He has researched a range of treatments including chemotherapy regimens, immunotherapy, and combination therapies aimed at improving outcomes for lymphoma patients.
Is Dr. Rosenfelt's work relevant to patients with relapsed lymphoma?
Yes, his studies focus on patients with relapsed lymphoma, exploring treatments that can lead to better recovery outcomes.
What is the significance of his research on immunotherapy?
His research on immunotherapy has shown promising results, with a significant percentage of patients responding positively, which could lead to improved therapies for non-Hodgkin lymphoma.
Publications in plain English
Concurrent inhibition of MYC and BCL2 is a potentially effective treatment strategy for double hit and triple hit B-cell lymphomas.
2015
Leukemia research
Cinar M, Rosenfelt F, Rokhsar S, Lopategui J, Pillai R +4 more
Plain English This study focused on double hit and triple hit B-cell lymphomas, which are aggressive types of cancer that often lead to poor survival rates due to limited treatment options. Researchers tested several drugs and found that using a combination of two specific inhibitors (10058-F4 and JQ-1) alongside BCL2 inhibitor ABT-199 significantly reduced cancer cell growth compared to using each drug alone. This approach seems effective because it triggers cancer cell death, which can improve treatment outcomes for patients with these challenging lymphomas.
Who this helps: Patients with double hit and triple hit B-cell lymphomas.
A phase 2 trial of immunotherapy with mitumprotimut-T (Id-KLH) and GM-CSF following rituximab in follicular B-cell lymphoma.
2010
Journal of immunotherapy (Hagerstown, Md. : 1997)
Koç ON, Redfern C, Wiernik PH, Rosenfelt F, Winter JN +5 more
Plain English Researchers studied a new immunotherapy treatment called mitumprotimut-T combined with GM-CSF for patients with follicular B-cell lymphoma after they had received rituximab. Out of 92 patients, 60% responded positively to the treatment, with an average event-free survival time of about 15 months. This approach shows promise because it could help improve patient outcomes and guides further research into more effective cancer therapies.
Who this helps: This helps patients with follicular B-cell lymphoma.
Mitoxantrone/ifosfamide/etoposide salvage regimen with rituximab for in vivo purging in patients with relapsed lymphoma.
2002
Clinical lymphoma
Emmanouilides C, Lill M, Telatar M, Rosenfelt F, Grody W +2 more
Plain English This study looked at using rituximab alongside a specific chemotherapy regimen (mitoxantrone, ifosfamide, and etoposide) to better prepare stem cells for patients with recurring B-cell lymphoma before they undergo a stem cell transplant. Out of 15 patients who initially had signs of cancer in their cells, 10 ended up with cancer-free stem cells after treatment, which is a significant improvement. This matters because having clean stem cells can lead to better outcomes after transplant and potentially help patients recover more effectively.
Who this helps: Patients with B-cell lymphoma undergoing stem cell transplants.
A fatal hyperpyrexial response to bleomycin following prior therapy: a case report and literature review.
1982
The Yale journal of biology and medicine
Rosenfelt F, Palmer J, Weinstein I, Rosenbloom B
Plain English In this study, researchers examined a rare and severe reaction called hyperpyrexia—extremely high fever—after administering bleomycin, a drug commonly used to treat cancer. They reported a case where a patient experienced this fatal reaction after having received the drug without issues in the past, highlighting that such risks can occur even after prior successful treatments. Understanding this risk is crucial for better patient management and safety during cancer therapy.
Who this helps: This helps doctors and oncologists make safer treatment decisions for their patients.
Diffuse histiocytic lymphoma presenting with gastrointestinal tract lesions. The Stanford experience.
1980
Cancer
Rosenfelt F, Rosenberg SA
Plain English This study looked at 284 patients with diffuse histiocytic lymphoma (DHL) who were treated at Stanford from 1970 to 1978, focusing specifically on those with gastrointestinal issues. Out of these patients, 48 had problems in their digestive systems, with abdominal pain being the most common symptom and 56% having stomach involvement. After treatment, 54% of patients went into complete remission, with those achieving remission surviving for more than 36 months on average, which highlights the need for improved treatment approaches.
Who this helps: This information benefits doctors treating patients with diffuse histiocytic lymphoma, particularly those with gastrointestinal complications.